Terms: = Sarcomas AND PAX3, MGC120382, 5077, ENSG00000135903, CDHS, MGC120383, HUP2, P23760, WS1, MGC120384, MGC134778, MGC120381 AND Treatment
85 results:
1. treatment of nasolabial fold rhabdomyosarcoma in children: A single-institution experience.
Zhang G; Sun N; Ni X; Su Y; He L; Liu Z; Zhang J; Li Y; Zhang X; Liu Q; Liu Z; Li X; Mei L; Liu Y; Ji T; Wang S
Head Neck; 2024 Apr; 46(4):905-914. PubMed ID: 38214480
[TBL] [Abstract] [Full Text] [Related]
2. Pharmacological EZH2 inhibition combined with retinoic acid treatment promotes differentiation and apoptosis in rhabdomyosarcoma cells.
O'Brien E; Tse C; Tracy I; Reddin I; Selfe J; Gibson J; Tapper W; Pengelly RJ; Gao J; Aladowicz E; Petts G; Thway K; Popov S; Kelsey A; Underwood TJ; Shipley J; Walters ZS
Clin Epigenetics; 2023 Oct; 15(1):167. PubMed ID: 37858275
[TBL] [Abstract] [Full Text] [Related]
3. Significance of fusion status, Oberlin risk factors, local and maintenance treatment in pediatric and adolescent patients with metastatic rhabdomyosarcoma: Data of the European Soft Tissue Sarcoma Registry SoTiSaR.
Heinz AT; Schönstein A; Ebinger M; Fuchs J; Timmermann B; Seitz G; Vokuhl C; Münter M; Pajtler KW; Stegmaier S; von Kalle T; Kratz CP; Ljungman G; Juntti H; Klingebiel T; Koscielniak E; Sparber-Sauer M;
Pediatr Blood Cancer; 2024 Jan; 71(1):e30707. PubMed ID: 37814424
[TBL] [Abstract] [Full Text] [Related]
4. Biphenotypic sinonasal sarcoma-A recently described entity with many mimics: A case report.
Ingle A; Mahendra N; Gopal Reddy GV
Indian J Pathol Microbiol; 2023; 66(2):396-399. PubMed ID: 37077095
[TBL] [Abstract] [Full Text] [Related]
5. Biphenotypic Sinonasal Sarcoma: Case Reports of Diagnostic Findings and Clinical Management of 3 Cases.
Augustin Y; Zaidi S; Jones RL; Benson C; Simcock R; Fisher C; Thway K; Hallin M; Miah AB
Anticancer Res; 2023 Apr; 43(4):1581-1589. PubMed ID: 36974788
[TBL] [Abstract] [Full Text] [Related]
6. Metastatic rhabdomyosarcoma with exclusive distant lymph node involvement: A European Pediatric Soft tissue sarcoma Study Group (EpSSG) report.
Mercolini F; Merks JHM; Minard-Colin V; Cameron A; van Scheltinga SEJT; Sher O; Fichera G; Orbach D; Glosli H; Coppadoro B; Gallego S; Chisholm JC; Bisogno G
Pediatr Blood Cancer; 2023 Mar; 70(3):e30143. PubMed ID: 36519598
[TBL] [Abstract] [Full Text] [Related]
7. Translational Implications for Radiosensitizing Strategies in Rhabdomyosarcoma.
Pomella S; Porrazzo A; Cassandri M; Camero S; Codenotti S; Milazzo L; Vulcano F; Barillari G; Cenci G; Marchese C; Fanzani A; Megiorni F; Rota R; Marampon F
Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36362070
[TBL] [Abstract] [Full Text] [Related]
8. Molecular Characterization of Circulating Tumor DNA in Pediatric Rhabdomyosarcoma: A Feasibility Study.
Ruhen O; Lak NSM; Stutterheim J; Danielli SG; Chicard M; Iddir Y; Saint-Charles A; Di Paolo V; Tombolan L; Gatz SA; Aladowicz E; Proszek P; Jamal S; Stankunaite R; Hughes D; Carter P; Izquierdo E; Wasti A; Chisholm JC; George SL; Pace E; Chesler L; Aerts I; Pierron G; Zaidi S; Delattre O; Surdez D; Kelsey A; Hubank M; Bonvini P; Bisogno G; Di Giannatale A; Schleiermacher G; Schäfer BW; Tytgat GAM; Shipley J
JCO Precis Oncol; 2022 Oct; 6():e2100534. PubMed ID: 36265118
[TBL] [Abstract] [Full Text] [Related]
9. Neomorphic DNA-binding enables tumor-specific therapeutic gene expression in fusion-addicted childhood sarcoma.
Hölting TLB; Cidre-Aranaz F; Matzek D; Popper B; Jacobi SJ; Funk CM; Geyer FH; Li J; Piseddu I; Cadilha BL; Ledderose S; Zwilling J; Ohmura S; Anz D; Künkele A; Klauschen F; Grünewald TGP; Knott MML
Mol Cancer; 2022 Oct; 21(1):199. PubMed ID: 36229873
[TBL] [Abstract] [Full Text] [Related]
10. Therapeutic targeting of ATR in alveolar rhabdomyosarcoma.
Dorado García H; Pusch F; Bei Y; von Stebut J; Ibáñez G; Guillan K; Imami K; Gürgen D; Rolff J; Helmsauer K; Meyer-Liesener S; Timme N; Bardinet V; Chamorro González R; MacArthur IC; Chen CY; Schulz J; Wengner AM; Furth C; Lala B; Eggert A; Seifert G; Hundsoerfer P; Kirchner M; Mertins P; Selbach M; Lissat A; Dubois F; Horst D; Schulte JH; Spuler S; You D; Dela Cruz F; Kung AL; Haase K; DiVirgilio M; Scheer M; Ortiz MV; Henssen AG
Nat Commun; 2022 Jul; 13(1):4297. PubMed ID: 35879366
[TBL] [Abstract] [Full Text] [Related]
11. Molecular testing of rhabdomyosarcoma in clinical trials to improve risk stratification and outcome: A consensus view from European paediatric Soft tissue sarcoma Study Group, Children's Oncology Group and Cooperative Weichteilsarkom-Studiengruppe.
Hettmer S; Linardic CM; Kelsey A; Rudzinski ER; Vokuhl C; Selfe J; Ruhen O; Shern JF; Khan J; Kovach AR; Lupo PJ; Gatz SA; Schäfer BW; Volchenboum S; Minard-Colin V; Koscielniak E; Hawkins DS; Bisogno G; Sparber-Sauer M; Venkatramani R; Merks JHM; Shipley J
Eur J Cancer; 2022 Sep; 172():367-386. PubMed ID: 35839732
[TBL] [Abstract] [Full Text] [Related]
12. MS-275 (Entinostat) Promotes Radio-Sensitivity in pax3-FOXO1 Rhabdomyosarcoma Cells.
Cassandri M; Pomella S; Rossetti A; Petragnano F; Milazzo L; Vulcano F; Camero S; Codenotti S; Cicchetti F; Maggio R; Festuccia C; Gravina GL; Fanzani A; Megiorni F; Catanoso M; Marchese C; Tombolini V; Locatelli F; Rota R; Marampon F
Int J Mol Sci; 2021 Oct; 22(19):. PubMed ID: 34639012
[TBL] [Abstract] [Full Text] [Related]
13. Congenital rhabdomyosarcoma: A report from the European paediatric Soft tissue sarcoma Study Group.
Bisogno G; Minard-Colin V; Arush MB; Daragjati J; Coppadoro B; Gallego S; Alaggio R; Smeulders N; Mudry P; Zin A; Merks JHM; Slater O
Pediatr Blood Cancer; 2022 Feb; 69(2):e29376. PubMed ID: 34582098
[TBL] [Abstract] [Full Text] [Related]
14. A case of primary CNS embryonal rhabdomyosarcoma with pax3-NCOA2 fusion and systematic meta-review.
Tanaka R; Inoue K; Yamada Y; Yoshida M; Shima H; Ito J; Okita H; Miwa T; Kato M; Shimada H
J Neurooncol; 2021 Sep; 154(2):247-256. PubMed ID: 34398431
[TBL] [Abstract] [Full Text] [Related]
15. A Review of Effusion Cytomorphology of Small Round Cell Tumors.
Han LM; VandenBussche CJ; Abildtrup M; Chandra A; Vohra P
Acta Cytol; 2022; 66(4):336-346. PubMed ID: 34218227
[TBL] [Abstract] [Full Text] [Related]
16. Changes in FXR1 expression after Chemotherapy for Rhabdomyosarcoma.
Xu MC; Ghani MO; Apple A; Chen H; Whiteside M; Borinstein SC; Correa H; Lovvorn HN
J Pediatr Surg; 2021 Jun; 56(6):1148-1156. PubMed ID: 33736876
[TBL] [Abstract] [Full Text] [Related]
17. FOXF1 is required for the oncogenic properties of pax3-FOXO1 in rhabdomyosarcoma.
Milewski D; Shukla S; Gryder BE; Pradhan A; Donovan J; Sudha P; Vallabh S; Pyros A; Xu Y; Barski A; Szabo S; Turpin B; Pressey JG; Millay DP; Khan J; Kalinichenko VV; Kalin TV
Oncogene; 2021 Mar; 40(12):2182-2199. PubMed ID: 33627785
[TBL] [Abstract] [Full Text] [Related]
18. Rhabdomyosarcoma: From Obscurity to Clarity in Diagnosis … But With Ongoing Challenges in Management: The Farber-Landing Lecture of 2020.
Parham DM; Giannikopoulos P
Pediatr Dev Pathol; 2021; 24(2):87-95. PubMed ID: 33439112
[TBL] [Abstract] [Full Text] [Related]
19. Orbital Involvement by Biphenotypic Sinonasal Sarcoma With a Literature Review.
Hanbazazh M; Jakobiec FA; Curtin HD; Lefebvre DR
Ophthalmic Plast Reconstr Surg; 2021 Jul-Aug 01; 37(4):305-311. PubMed ID: 32991500
[TBL] [Abstract] [Full Text] [Related]
20. A human Myogenin promoter modified to be highly active in alveolar rhabdomyosarcoma drives an effective suicide gene therapy.
Pruller J; Hofer I; Ganassi M; Heher P; Ma MT; Zammit PS
Cancer Gene Ther; 2021 May; 28(5):427-441. PubMed ID: 32973362
[TBL] [Abstract] [Full Text] [Related]
[Next]
